Potential HCV Drug INX-189 Completes Initial Safety Trial
INX-189, Inhibitex's nucleotide polymerase inhibitor in development to fight chronic Hepatitis C, passes the first stage of human testing by demonstrating its safety.
Continue reading »Hepatitis C Treatments/Therapies
Fast Track Granted to HCV Drug PSI-7977
Combining antiviral activity with a barrier to resistance, Pharmasset Inc.'s Hepatitis C drug, PSI-7977, has received fast track status by the FDA.
Continue reading »Telaprevir Improves and Shortens Hepatitis C Treatment
Due to recently released Phase III trial results, telaprevir has a better chance of gaining FDA approval by 2011. Researchers found that adding telaprevir to pegylated interferon and ribavirin takes half the time to achieve superior results than does standard Hepatitis C therapy.
Continue reading »Anti-Diabetic Drugs Thwart the Hepatitis C Virus
By analyzing the role of the AMP kinase enzyme in Hepatitis C viral proliferation, University of Leeds researchers have discovered that certain traditional diabetes drugs prevent Hepatitis C viral replication.
Continue reading »Boceprevir Meets Key Hep C Goals
Late-stage studies show that boceprevir remains a Hepatitis C drug contender.
Continue reading »Advanced Telaprevir Trial Cures 75 Percent of HCV
Data from a Phase III trial examining telaprevir's safety and efficacy for Hepatitis C has just been released - and it is great news!
Continue reading »Improving HCV Response With Insulin Resistance
Could insulin resistance be getting in the way of your Hepatitis C treatment? To manage this possible complication, discover why many experts advise prescribing medications to manage insulin resistance in an effort to improve Hepatitis C treatment outcomes.
Continue reading »Hepatitis C Cure Likely in Multiple Drug Therapy
Based on sophisticated computer and mathematical modeling, researchers predict that a combination of drugs designed to fight three or more mutated strains of Hepatitis C simultaneously is needed to better eradicate this virus.
Continue reading »Experimental Drug Drops Hep C Viral Load by Nearly 100%
Apr 27, 2010
1 Comment
Early results from a Phase II study demonstrate that Bristol-Myers Squibb's experimental drug has unrivaled potency against the Hepatitis C virus.
Continue reading »Locteron Improves HCV Therapy
Interim Phase II study results showed that, when paired with ribavirin, Locteron demonstrated potency against Hepatitis C similar to pegylated interferon. In addition, Locteron demonstrated 57 percent fewer adverse effects at a more favorable dosing schedule of once every other week.
Continue reading »
